Clinical Report: Fulminant-like Diabetes and Hyperosmolar Hyperglycemic State Associated with Inavolisib

Overview

This report details a case of a 59-year-old female with metastatic breast cancer who developed fulminant-like diabetes and Hyperosmolar Hyperglycemic State (HHS) after starting Inavolisib. Rapid recognition and management of hyperglycemia are critical due to the potential for severe complications.

Background

Incorporate statistics or references regarding the incidence of hyperglycemia associated with Inavolisib.

Data Highlights

Key Findings

• Inavolisib can induce rapid-onset hyperglycemia and HHS within days of treatment initiation.
• Patients may present with severe hyperglycemia despite normal baseline glycemic indices.
• Intensive insulin therapy can effectively resolve Inavolisib-induced hyperglycemia.
• Close glucose monitoring is essential for patients receiving Inavolisib.
• Early metabolic assessment and prompt discontinuation of Inavolisib are critical in managing hyperglycemic emergencies.

Clinical Implications

Clinicians should be vigilant for signs of hyperglycemia in patients treated with Inavolisib, even if they have no prior history of diabetes. Early intervention with insulin therapy and close monitoring can prevent progression to severe hyperglycemic states.

Conclusion

Inavolisib poses a significant risk for acute hyperglycemia and HHS, necessitating proactive management strategies to ensure patient safety and effective treatment outcomes.

Related Resources & Content

1. FDA, Drugs Trials Snapshot: ITOVEBI, 2024 -- Inavolisib Approval and Hyperglycemia Risks
2. Cleveland Clinic Journal of Medicine, 2024 -- Hyperglycemic crises in adults: A look at the 2024 consensus report
3. ScienceDirect, Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer, 2025 -- Management of PI3K Inhibitor Toxicities
4. The Journal of Clinical Endocrinology & Metabolism — Management of Patients with Diabetes Resulting from Exocrine Pancreatic Disorders
5. Ophthalmology Management — Additional Ophthalmic Complications Associated With GLP1 Use Identified in Case Series
6. The Journal of Clinical Endocrinology & Metabolism — Reply to Hao and Xue's Letter to the Editor: “Characteristics of Checkpoint Inhibitor-Induced Autoimmune Diabetes Mellitus Include C-Peptide Depletion and Pancreatic Atrophy”
7. the ophthalmologist — Wegovy and Possible Vision Risk
8. Management of Patients with Diabetes Resulting from Exocrine Pancreatic Disorders
9. Additional Ophthalmic Complications Associated With GLP1 Use Identified in Case Series
10. Drugs Trials Snapshot: ITOVEBI | FDA
11. Hyperglycemic crises in adults: A look at the 2024 consensus report | Cleveland Clinic Journal of Medicine
12. Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer - ScienceDirect